Chimerix
agonist distinct molecular target and efficacy profile relative to efficacy in preclinical models of advanced cancers tox studies complete potential to advance to partnerships established for early stage clinical trials with brown university and cancer center preclinical studies are ongoing to evaluate additional oncology indications and predictive for for clinical development pancreatic cancer model shows the potential of | Chimerix
Company
Deck Type
Sector
Industry
Deck date
August 2023
Slide
38 of 43
Similar slides by Chimerix
See diffirences between slides (animation)
Investor Presentation
May 2023
agonist | Chimerix
Investor Presentation
March 2023
agonist | Chimerix
Related slides by other companies
Boundless Bio
IPO
March 2024
spyglass reveals cancer targets both novel and validated that intersect distinct nodes of | Boundless Bio
MindMed
Investor Presentation
June 2023
preclinical data indicate potential enhanced benefit risk profile | MindMed
Exscientia
Investor Day
January 2024
enabling studies complete | Exscientia
Taysha
IPO
September 2020
efficacy outperformed unregulated in mouse survival study | Taysha
Other recent decks by Chimerix
See all presentations (6 decks)
Investor Presentation
May 2023
Investor Presentation
March 2023
Results
March 2022
Investor Conference
November 2021
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io